Nutex Health Inc

Nutex Health reported a second-quarter 2026 net income of $65.8 million, or $9.38 per diluted share, reversing a net loss of $17.7 million a year earlier. A favorable amendment to the company's agreement with HaloMD and a reduction in the CMS administrative fee for the federal Independent Dispute Resolution process cut contract services expenses by $52.3 million during the quarter. Hospital division visits increased 9.6% year over year to 49,962, while same-hospital visits rose 6.3%. Total revenue declined 13.6% to $210.8 million, which the company attributed to favorable early-stage IDR improvements realized in the first half of 2025. Nutex Health ended the quarter with $205.2 million in cash and $31.1 million in long-term debt, and expects to open three new hospitals later in 2026.

Nutex Health saw its revenue triple and profit grow nearly twelvefold after it began filing arbitration disputes under the No Surprises Act, according to a STAT report on June 29. The development highlights how the company's microhospital model ties performance closely to reimbursement outcomes and payer disputes. Analysts have an average price target implying about 25.4% upside for the stock, though wider target dispersion makes the risk-reward profile less straightforward. The upside case depends on whether Nutex can sustain profitability while navigating scrutiny around out-of-network billing and reimbursement rules.